Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accounts Payables: 2009-2024

Historic Accounts Payables for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $17.0 million.

  • Northwest Biotherapeutics' Accounts Payables rose 50.03% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 50.03%. This contributed to the annual value of $17.0 million for FY2024, which is 65.65% up from last year.
  • According to the latest figures from FY2024, Northwest Biotherapeutics' Accounts Payables is $17.0 million, which was up 65.65% from $10.2 million recorded in FY2023.
  • Northwest Biotherapeutics' Accounts Payables' 5-year high stood at $17.0 million during FY2024, with a 5-year trough of $7.0 million in FY2021.
  • Moreover, its 3-year median value for Accounts Payables was $10.7 million (2022), whereas its average is $12.6 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Accounts Payables dropped by 5.47% in 2021 and then spiked by 65.65% in 2024.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Accounts Payables stood at $7.4 million in 2020, then decreased by 5.47% to $7.0 million in 2021, then soared by 53.20% to $10.7 million in 2022, then dropped by 4.15% to $10.2 million in 2023, then skyrocketed by 65.65% to $17.0 million in 2024.